Related Experiment Video
Updated: Mar 5, 2026

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
Published on: February 14, 2022
The evolution and benefit of device therapy in patients listed for heart transplant
Bert Vandenberk1,2, Mark Hinderks3, Gabor Voros2
1Department of Cardiovascular Sciences, University of Leuven, Herestraat 49, 3000 Leuven, Belgium.
Insights
Implantable cardioverter-defibrillators (ICDs) may improve survival for heart transplant candidates awaiting longer wait times. Despite increased device use, transplant rates remained stable, highlighting the need for effective arrhythmia management in this high-risk population.
Area of Science:
- Cardiology
- Transplantation Medicine
- Medical Device Therapy
Background:
- The 2015 ESC Guidelines recommend implantable cardioverter-defibrillators (ICDs) for heart transplant candidates.
- This recommendation is based on expert consensus due to limited data.
Purpose of the Study:
- To evaluate the impact of ICD implantation on survival and outcomes in patients listed for heart transplantation.
- To analyze trends in waiting list times, device use, and transplant rates.
Main Methods:
- Retrospective study of 286 heart transplant candidates (2002-2014).
- Inclusion criteria: age >= 16, ischemic or dilated cardiomyopathy, first-time transplant. Exclusion criteria: other cardiac diseases, re-transplantation.
- Data collected on ICD implantation, left ventricular assist device (LVAD) use, waiting times, and survival.
Main Results:
- Waiting list times and the use of ICDs and LVADs significantly increased over time.
- The proportion of patients receiving a heart transplant remained unchanged.
- The annual appropriate ICD shock rate was 28.0%/year.
- Patients with ICDs showed a trend towards improved survival (P=0.070).
- Independent predictors of mortality or removal from the list included LVAD need, stroke history, older age, and poorer renal function.
Conclusions:
- Increased waiting times for heart transplantation necessitate advanced device support.
- Implantable cardioverter-defibrillators (ICDs) may offer survival benefits for heart transplant candidates at risk of sudden cardiac death.
- The study highlights the evolving management strategies for patients awaiting heart transplantation.
Aims:
The latest 2015 ESC Guidelines on the prevention of sudden cardiac death make a Class IIa recommendation for ICD implantation in patients listed for heart transplantation. This recommendation was based on expert consensus in view of the sparsity of data.
Methods And Results:
All patients listed for heart transplantation at the University Hospitals of Leuven from 2002 until 2014 were studied retrospectively. Exclusion criteria were age <16 years, cardiac disease other than ischaemic or dilated cardiomyopathy and re-transplantation. A total of 286 patients were included, of which 140 (49.0%) received an ICD. There was a historical increase of the time on the waiting list before transplantation (P < 0.001) together with an increase of the use of ICDs (P < 0.001) and left ventricular assist devices (LVADs) (P < 0.001). The proportion of patients reaching heart transplant remained unchanged (P = 0.700). The annual appropriate shock rate in patients with ICD was 28.0%/y on the active waiting list. Patients with ICD showed a trend to improved survival (P = 0.070). Independent predictors of mortality or removal from the transplant list because of clinical deterioration were the need for LVAD (HR 4.38, 95%CI 2.11-9.01), a history of stroke (HR 2.95, 95%CI 1.61-5.40), older age (HR 1.03, 95%CI 1.01-1.05) and a worse renal function (HR 1.15, 95%CI 1.00-1.33).
Conclusion:
The time on the waiting list for heart transplantation significantly increased together with an increased use of device therapy in this population. The proportion of patients reaching transplant remained unchanged. This patient group is prone to life-threatening arrhythmias and the use of an ICD may improve survival.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Heart Failure VI: Adjunct Therapies
Cardiomyopathy II: Dilated Cardiomyopathy
Kidney Transplant I: Introduction
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

